 |
|
Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products
Thomas J. Moore;
Christopher S. Walsh, PharmD;
Michael R. Cohen, RPh, MS, DSc
Arch Intern Med. 2004;164:1192-1196.
Background Methemoglobinemia (MHb) is characterized by abnormal levels of oxidized hemoglobin that cannot bind and transport oxygen. When induced by benzocaine anesthetic spray and other chemicals, it can result in cyanosis and life-threatening complications.
Methods From 818 439 adverse event reports received by the US Food and Drug Administration from November 1997 through March 2002, we extracted every report for use of a benzocaine product. We classified each case by product type (eg, spray, gel, or solution), by whether MHb was involved, and by the dose given.
Results Among 198 reported adverse events of all types associated with benzocaine, 132 cases (66.7%) involved definite or probable MHb. The MHb cases included 107 serious adverse events (81.1%) and 2 deaths (1.5%). In 123 cases (93.2%), the product was a spray; in 2 cases (1.5%), a benzocaine-containing lozenge; and 1 case, a gel. In the 69 cases that specified a dose, 37 (53.6%) indicated that a single spray was applied (approximately the recommended amount).
Conclusions Health professionals involved in endoscopy, intubation, bronchoscopy, or similar invasive procedures using benzocaine-containing sprays should know that (1) administration may cause MHb with potentially serious consequences, (2) identifying the reaction to benzocaine usually requires cooximetry (although it can be implied by symptoms), and (3) treatment involves immediate intravenous administration of 1 to 2 mg/kg of methylene blue.
From the Institute for Safe Medication Practices, Huntingdon Valley, Pa (Mr Moore and Drs Walsh and Cohen), and the Center for Health Services Research and Policy, The George Washington University School of Public Health and Health Services, Washington, DC (Mr Moore). The authors have no relevant financial interest in this article.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Severe Methemoglobinemia From Topical Benzocaine 7.5% (Baby Orajel) Use for Teething Pain in a Toddler
Bong et al.
CLIN PEDIATR 2009;48:209-211.
Toxicology in the Critical Care Unit
Alapat and Zimmerman
Chest 2008;133:1006-1013.
ABSTRACT
| FULL TEXT
Benzocaine: Not Dangerous Enough?
Calello et al.
Pediatrics 2005;115:1452-1452.
FULL TEXT
Methemoglobinemia Secondary to Topical Benzocaine Use in a Lung Transplant Patient
LeClaire et al.
The Annals of Pharmacotherapy 2005;39:373-376.
ABSTRACT
| FULL TEXT
|
